Last updated: February 19, 2026
This analysis details the scope and claims of Brazilian patent BR112015022972, focusing on its pharmaceutical compositions and methods of treatment. The patent, filed on September 14, 2015, by Pfizer Inc., claims a specific formulation of a JAK inhibitor and its use in treating inflammatory and autoimmune diseases. Understanding the breadth of these claims and the existing patent landscape is critical for R&D and investment decisions within the pharmaceutical sector.
What Does Brazilian Patent BR112015022972 Claim?
Patent BR112015022972, titled "PHARMACEUTICAL COMPOSITIONS COMPRISING A KINASE INHIBITOR AND A BUFFERING AGENT AND METHODS OF USING THE SAME," protects a specific pharmaceutical formulation. The core of the patent lies in the combination of a Janus Kinase (JAK) inhibitor with a buffering agent.
Key Claimed Components
The patent's claims center around a pharmaceutical composition that comprises:
- A JAK Inhibitor: The patent specifies various JAK inhibitors, including but not limited to compounds that inhibit JAK1, JAK2, JAK3, and TYK2. Notably, the patent lists Tofacitinib as a primary example of such an inhibitor, though other JAK inhibitors are encompassed within the scope.
- A Buffering Agent: This component is crucial for stabilizing the JAK inhibitor, particularly in aqueous environments. The buffering agent maintains the pH of the composition within a specified range, thereby enhancing the stability and shelf-life of the active pharmaceutical ingredient. Examples of buffering agents include citrate salts, phosphate salts, and acetate salts.
- A Pharmaceutical Acceptable Carrier: This includes diluents, excipients, and other inactive ingredients necessary for formulation.
The patent outlines specific ranges for the concentrations of the JAK inhibitor and the buffering agent, which are designed to achieve optimal stability and efficacy.
Scope of Treatment
The methods of use claims in BR112015022972 focus on treating diseases mediated by aberrant JAK signaling. These include a broad spectrum of inflammatory and autoimmune conditions.
- Targeted Diseases: The patent explicitly mentions conditions such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis), and psoriasis. The claimed methods involve administering the pharmaceutical composition to a subject in need thereof.
- Dosage and Administration: While the patent does not mandate specific dosages, it implies that the composition is formulated for effective therapeutic delivery, typically through oral administration. The stability provided by the buffering agent is intended to ensure consistent drug delivery and bioavailability.
The patent's broad claims on JAK inhibitors, when formulated with a buffering agent, create a significant intellectual property barrier for competing products targeting similar indications.
What is the Patent Landscape for JAK Inhibitor Formulations in Brazil?
The patent landscape for JAK inhibitors, particularly in Brazil, is competitive and dynamic. Several companies hold patents related to different JAK inhibitors, their formulations, and their therapeutic applications. Brazilian patent BR112015022972, held by Pfizer Inc., is a key piece of this landscape due to its focus on a specific formulation strategy that enhances drug stability.
Key Players and Their Patents
While a comprehensive analysis would require exhaustive searching, several major pharmaceutical companies are active in the JAK inhibitor space. These include:
- AbbVie Inc.: Known for Upadacitinib (Rinvoq).
- Eli Lilly and Company: Known for Baricitinib (Olumiant).
- Incyte Corporation: Known for Ruxolitinib (Jakafi).
- Pfizer Inc.: Holds patents on Tofacitinib (Xeljanz) and its various formulations, including BR112015022972.
These companies have filed patents covering:
- New Chemical Entities (NCEs): Novel JAK inhibitor molecules.
- Formulations: Improved delivery systems, stability enhancements, and different dosage forms.
- Methods of Treatment: Specific indications and patient populations for which JAK inhibitors can be used.
Patent Protection Strategies
Companies employ several strategies to secure and maintain broad patent protection in the JAK inhibitor arena:
- Composition of Matter Patents: These are the strongest patents, protecting the molecule itself.
- Formulation Patents: As seen with BR112015022972, these protect specific combinations of active ingredients and excipients that offer advantages like improved stability, bioavailability, or reduced side effects.
- Method of Use Patents: These protect the use of a known drug for treating a new disease or patient subgroup.
- Polymorph Patents: Protecting specific crystalline forms of an active pharmaceutical ingredient, which can affect solubility and stability.
The Brazilian patent system, governed by the National Institute of Industrial Property (INPI), grants patents for novel inventions that are new, involve an inventive step, and have industrial applicability. The examination process is thorough, and patent holders must maintain their patents through payment of annuities.
Impact of BR112015022972 on the Landscape
Patent BR112015022972 specifically targets the formulation of JAK inhibitors. This means that even if a competitor has a patent on a JAK inhibitor molecule, they may be blocked from using a formulation that includes a buffering agent designed to enhance stability, as claimed by Pfizer. This type of patent is crucial for defending market share and preventing generic competition for established drugs. For instance, if Tofacitinib faces or has faced generic challenges, this formulation patent would be a key tool to maintain exclusivity for specific dosage forms.
What Are the Key Technical Aspects of BR112015022972?
The technical innovation protected by Brazilian patent BR112015022972 lies in the chemical and pharmaceutical engineering of a JAK inhibitor formulation. The patent addresses the inherent instability of certain JAK inhibitors, particularly in the presence of moisture or at certain pH levels.
Stability of JAK Inhibitors
Many JAK inhibitors, including Tofacitinib, are susceptible to degradation pathways that can reduce their potency and potentially lead to the formation of harmful byproducts. This degradation can be exacerbated by factors such as:
- pH Variability: The stability of a drug is highly dependent on the pH of its environment. Many amine-containing compounds, common in drug molecules like JAK inhibitors, are sensitive to pH fluctuations.
- Hydrolysis: Water can directly cleave chemical bonds within the drug molecule, leading to degradation.
- Oxidation: Exposure to oxygen can also initiate degradation processes.
The use of a buffering agent is a well-established pharmaceutical strategy to mitigate these issues. By maintaining a specific pH range, the buffering agent stabilizes the JAK inhibitor, preventing or slowing down degradation reactions.
Specific Formulation Advantages Claimed
BR112015022972 highlights several specific advantages conferred by the claimed formulation:
- Enhanced Chemical Stability: The primary benefit is the significant improvement in the chemical stability of the JAK inhibitor. This translates to a longer shelf-life for the pharmaceutical product.
- Improved Bioavailability: While not always directly claimed, increased stability often correlates with improved and more consistent bioavailability, as the active ingredient is less likely to degrade before absorption.
- Facilitation of Oral Administration: Stable formulations are essential for oral dosage forms, which require the drug to survive the acidic environment of the stomach and be absorbed in the intestine.
- Reduced Degradation Products: By minimizing degradation, the formulation also reduces the formation of potentially toxic byproducts.
The patent provides specific examples of buffering agents, such as sodium citrate and dibasic sodium phosphate, and outlines the required pH ranges, typically between 4.0 and 7.0, for optimal stabilization. The concentration of the buffering agent is also specified to be effective in maintaining this pH.
Examples and Data Presented in the Patent
While specific numerical data on degradation rates or stability profiles are proprietary to the patent holder and may not be fully disclosed in the public patent document, the patent typically includes experimental data or detailed descriptions of how the formulation was developed and tested. This often involves:
- Excipient Screening: Testing various buffering agents and other excipients to identify optimal combinations.
- Stability Studies: Conducting accelerated and long-term stability studies under various environmental conditions (e.g., temperature, humidity) to assess the degradation of the JAK inhibitor in the presence and absence of the buffering agent.
- pH Measurements: Demonstrating the ability of the buffering agent to maintain the desired pH over time.
The patent's technical merit rests on its demonstration that this specific combination of a JAK inhibitor and a buffering agent provides a tangible and patentable improvement over existing formulations.
What are the Commercial and Strategic Implications of BR112015022972?
The commercial and strategic implications of Brazilian patent BR112015022972 are substantial, particularly for Pfizer Inc. and its competitors in the JAK inhibitor market. This patent represents a significant asset in protecting market exclusivity and influencing market dynamics.
Market Exclusivity and Competition
- Extended Market Protection: For Pfizer Inc., this patent provides a layer of protection for its JAK inhibitor products (e.g., Tofacitinib). Even as the primary composition of matter patent on the active ingredient approaches or expires, formulation patents can extend market exclusivity. This is crucial for recouping R&D investments and maintaining revenue streams.
- Blocking Competitor Formulations: BR112015022972 prevents other companies from marketing JAK inhibitor products that utilize a similar buffering strategy to achieve enhanced stability for the same class of drugs. This forces competitors to develop alternative formulations or different JAK inhibitors altogether, increasing their R&D costs and timelines.
- Impact on Generic Entry: The existence of such formulation patents can delay or complicate the entry of generic versions of JAK inhibitor drugs. Generic manufacturers must demonstrate non-infringement of all valid patents, including formulation patents, before they can launch their products.
Strategic R&D and Investment Considerations
- Pipeline Development: For companies developing new JAK inhibitors or seeking to improve existing ones, this patent highlights the importance of developing differentiated formulations. Investment in innovative formulation technologies, such as novel buffering systems or controlled-release mechanisms, can lead to new patentable inventions.
- Licensing and Collaboration Opportunities: Companies holding such patents may engage in licensing agreements, allowing other entities to use their patented formulations in exchange for royalties. Conversely, companies seeking to utilize specific formulation technologies may pursue licensing opportunities.
- Mergers and Acquisitions: The strategic value of a robust patent portfolio, including formulation patents, can influence mergers and acquisition decisions. Companies with strong IP assets are more attractive targets or can use their IP to acquire smaller entities with complementary technologies.
- Freedom-to-Operate (FTO) Analysis: Any company planning to develop or market a JAK inhibitor in Brazil must conduct a thorough FTO analysis to ensure their product does not infringe existing patents, including BR112015022972. This analysis involves reviewing active patents, their claims, and their expiry dates.
Regulatory and Pricing Dynamics
- Exclusivity Periods: In Brazil, patent terms are generally 20 years from the filing date. However, specific regulations can influence the effective market exclusivity, especially for pharmaceuticals. Understanding the interplay between patent expiry and regulatory approval is vital.
- Pricing Power: Extended market exclusivity due to formulation patents can allow pharmaceutical companies to maintain higher pricing for their products, impacting healthcare systems and patient access.
The strategic importance of BR112015022972 lies in its ability to shape the competitive landscape for JAK inhibitors in Brazil, influencing R&D priorities, investment decisions, and market access strategies for all stakeholders.
Key Takeaways
- Brazilian patent BR112015022972 protects pharmaceutical compositions containing a JAK inhibitor and a buffering agent, along with methods for treating inflammatory and autoimmune diseases.
- The patent's core innovation is the stabilization of JAK inhibitors through the use of buffering agents, enhancing chemical stability and shelf-life.
- The patent landscape for JAK inhibitors in Brazil is competitive, with multiple companies holding patents on various aspects of these drugs, including molecules, formulations, and methods of use.
- BR112015022972 provides Pfizer Inc. with a critical tool for extending market exclusivity for its JAK inhibitor products and preventing competitors from using similar stabilizing formulations.
- Strategically, the patent influences R&D direction, necessitates thorough freedom-to-operate analyses for new entrants, and impacts pricing and market access dynamics in the Brazilian pharmaceutical market.
Frequently Asked Questions
-
What specific JAK inhibitors are covered by patent BR112015022972?
The patent claims cover JAK inhibitors generally, with Tofacitinib explicitly mentioned as an example. It encompasses compounds that inhibit JAK1, JAK2, JAK3, and TYK2.
-
What is the primary purpose of the buffering agent in the claimed formulation?
The buffering agent is used to maintain the pH of the pharmaceutical composition within a specific range, thereby enhancing the chemical stability and shelf-life of the JAK inhibitor.
-
What types of diseases are targeted by the methods of treatment claimed in this patent?
The patent claims methods for treating diseases mediated by aberrant JAK signaling, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, inflammatory bowel disease (Crohn's disease and ulcerative colitis), and psoriasis.
-
How does patent BR112015022972 affect generic drug manufacturers in Brazil?
This patent can prevent generic manufacturers from launching products that utilize a similar buffering agent to stabilize JAK inhibitors, potentially delaying generic entry or requiring them to develop non-infringing formulations.
-
What is the expiry date of Brazilian patent BR112015022972?
As the patent was filed on September 14, 2015, its term in Brazil is 20 years from the filing date, meaning it is set to expire around September 14, 2035, barring any extensions or invalidations.
Citations
[1] Pfizer Inc. (2015). Pharmaceutical Compositions Comprising a Kinase Inhibitor and a Buffering Agent and Methods of Using the Same (Brazilian Patent BR112015022972). National Institute of Industrial Property (INPI).
